1. A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia
- Author
-
Andrea Mannucci, Adnan Nagrial, Catello Somma, Jason D. Lickliter, Jianjun Zou, Mark Voskoboynik, Michael Millward, Tarek Meniawy, Lianshan Zhang, Katherine Woods, Peter Grimison, Michael Lahn, Surein Arulananda, Hui K Gan, Pablo Fernandez-Penas, Andreas Behren, Bo Gao, Michelle Harrison, Howard Kallender, and Stacey Luo
- Subjects
0301 basic medicine ,Pharmacology ,Oncology ,medicine.medical_specialty ,medicine.drug_class ,Anti pd 1 ,Pharmaceutical Science ,Cancer ,First in human ,Monoclonal antibody ,medicine.disease ,03 medical and health sciences ,Dose finding ,030104 developmental biology ,0302 clinical medicine ,Australian population ,Pharmacokinetics ,030220 oncology & carcinogenesis ,Internal medicine ,Drug Discovery ,medicine ,In patient - Abstract
Purpose Camrelizumab inhibits PD-1 in non-clinical models and showed typical non-clinical pharmacokinetic (PK) and safety profiles for an IgG4 monoclonal antibody. We report results from the First-in-Human Phase 1 trial of camrelizumab in Australian population.
- Published
- 2020
- Full Text
- View/download PDF